Expect more with Siegfried as your preferred partner

Expect more with Siegfried as your preferred partner Siegfried at a glance

Overview • Commitment of some 850 employees • First choice in compliance, responsiveness and reliability • Over 130 years of continuity, global presence • Process Development experience from over 1, 600 substances, extensive services

Overview Our Vision Expect more with Siegfried as your preferred partner Bringing together our long-standing pharma and chemical heritage, we offer as an integrated partner benefit to our customers with more synergy, expertise and value. Explore more about how our broad range of custom development services, drug substance & drug product manufacturing capabilities, together with our existing product portfolio may help you achieve greater value. 3

Overview Locations 4

Overview Past do Present 1873 Pharmacist Samuel Benoni Siegfried founds a company with 12 employees as a supplier to pharmacies 1904 Conversion into a joint stock corporation 1937 Founding of Ganes Chemical Works, Inc. (NJ, USA) 1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 Focus on development and custom manufacturing 2001 Building of two core divisions: Siegfried and Sidroga 5

Overview Past to Present 2001 2005 2007 2008 2010 Integration of Ganes into the Siegfried Group = Siegfried (USA) Inc. Acquisition of Penick Corporation in New Jersey, USA Launch of a new pharmaceutical production facility in Malta Sale of the Sidroga Division Sale of the biotech activities Sale of the pharmaceutical production site Zofingen Definition of new strategy «Transform» Implementation of a new functionbased organisation. New investors and capital increase. Sale of Munich, Germany subsidiary (Pulmojet project) to Sanofi-Aventis. 6

Strategy Position 7

Products & Services Two Strong Business Areas Business Area Drug Substances Drug Products & Services Custom synthesis of APIs and intermediates, as well as production of standard substances, particularly controlles substances for analgesics and narcotics. Process development and production of complex drug products and finished dosage forms. 8

Management Board of Directors Gilbert Achermann Felix Meyer Chairman Reto Garzetti Andreas Casutt Reto Garzetti Thomas Villiger.

Management Executive Committee Rudolf Hanko Marianne Späne Chief Executive Officer Head Business Development & Sales Arnoud Middel Walter Kittl Head Human Resources Head Technical Operations Peter Gehler Wolfgang Wienand. Chief Scientific Officer, Head of Strategy Head Corporate Center Secretary to the Board of Directors Michael Hüsler Chief Financial Officer and M & A René Imwinkelried Head Research & Development

Human Resources Vision • • • Socially responsible employer Motivated and talented personnel Mutual respect • • Personal responsibility Focusing on results 11

Expect more with Siegfried as your preferred partner Thank you for your attention